{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:23:07Z","timestamp":1770711787446,"version":"3.49.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cluster B personality disorders (PDs) are considered some of the most severe mental health conditions. Scarce evidence exists about the real-world utilization of psychotropics for cluster B PD individuals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to uncover trends and patterns of psychotropic medication use among individuals diagnosed with cluster B PD in the year before and after their diagnosis and to identify factors associated with medication use in a large cohort of individuals newly diagnosed with cluster B PDs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a population-based observational study using Quebec\u2019s health services register. We identified Quebec residents aged \u226514 years and insured with the provincial drug plan with a first diagnosis of cluster B PD recorded between April 1, 2002, and March 31, 2019. Cluster B PD was defined with ICD-9\/10 diagnostic codes. We retrieved all claims for the main psychotropic medication classes: antipsychotics, antidepressants, anxiolytics, mood stabilizers, and attention-deficit\/hyperactivity disorder (ADHD) medications. We calculated the proportion of individuals exposed to these medication classes and analyzed trends over the years using robust Poisson regression models, adjusting for potential confounders. We used robust Poisson regression to identify factors associated with medication class use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 87,778 new cases of cluster B PD, with a mean age of 44.5\u2009years; 57.5% were women. Most frequent psychiatric comorbidities in the five years before cluster B PD diagnosis were depression (50.9%), anxiety (49.7%), and psychotic disorders (37.5%). Most individuals (71.0%) received at least one psychotropic during the year before cluster B PD diagnosis, and 78.5% received at least one of these medications in the subsequent year. The proportion of users increased after the diagnosis for antidepressants (51.6\u201354.7%), antipsychotics (35.9\u201345.2%), mood stabilizers (14.8\u201317.0%), and ADHD medications (5.1\u20135.9%), and remained relatively stable for anxiolytics (41.4\u201341.7%). Trends over time showed statistically significant increased use of antipsychotics and ADHD medications, decreased use of anxiolytics and mood stabilizers, and a stable use of antidepressants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Psychotropic medication use is highly prevalent among cluster B PD individuals. We observed an increase in medication use in the months following the diagnosis, particularly for antipsychotics, antidepressants, and mood stabilizers.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1243511","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T12:03:12Z","timestamp":1700740992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Psychotropic medication use pre and post-diagnosis of cluster B personality disorder: a Quebec\u2019s health services register cohort"],"prefix":"10.3389","volume":"14","author":[{"given":"Carlotta","family":"Lunghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Cailhol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Massamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elhadji A.","family":"Laouan Sidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Sirois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Rahme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Rochette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzane","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evens","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Biskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Lesage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"ref1","volume-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1192\/bjp.2018.202","article-title":"Prevalence of personality disorders in the general adult population in Western countries: systematic review and meta-analysis","volume":"213","author":"Volkert","year":"2018","journal-title":"Br J Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1177\/0706743717700818","article-title":"Prevalence, mortality, and health care use among patients with cluster B personality disorders clinically diagnosed in Quebec: a provincial cohort study, 2001-2012","volume":"62","author":"Cailhol","year":"2017","journal-title":"Can J Psychiatr"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1176\/appi.ps.202000554","article-title":"Utilization of health care services by patients with cluster B personality disorders or schizophrenia","volume":"72","author":"Cailhol","year":"2021","journal-title":"Psychiatr Serv Wash DC"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40479-018-0093-9","article-title":"Borderline personality disorder and substance use disorders: an updated review","volume":"5","author":"Trull","year":"2018","journal-title":"Borderline Pers Disord Emot Dysregulation"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"12436","DOI":"10.4088\/JCP.18m12436","article-title":"Deaths by suicide and other causes among patients with borderline personality disorder and personality-disordered comparison subjects over 24 years of prospective follow-up","volume":"80","author":"Temes","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/medicina55060223","article-title":"Suicidality in borderline personality disorder","volume":"55","author":"Paris","year":"2019","journal-title":"Medicina"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00406-019-00980-8","article-title":"Exploring the boundaries between borderline personality disorder and suicidal behavior disorder","volume":"270","author":"Ducasse","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14656566.2019.1686482","article-title":"Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough?","volume":"21","author":"Bozzatello","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-021-00855-4","article-title":"Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis","volume":"35","author":"Gartlehner","year":"2021","journal-title":"CNS Drugs"},{"key":"ref11","unstructured":"2009"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40479-019-0106-3","article-title":"European guidelines for personality disorders: past, present and future","volume":"6","author":"Simonsen","year":"2019","journal-title":"Borderline Pers Disord Emot Dysregulat"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e0264239","DOI":"10.1371\/journal.pone.0264239","article-title":"Evaluation of international guidance for the community treatment of \u2018personality disorders\u2019: a systematic review","volume":"18","author":"Wong","year":"2023","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"CD005653","DOI":"10.1002\/14651858.CD005653.pub2","article-title":"Pharmacological interventions for borderline personality disorder","author":"Stoffers","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s11920-014-0534-0","article-title":"Pharmacotherapy for borderline personality disorder--current evidence and recent trends","volume":"17","author":"Stoffers","year":"2015","journal-title":"Curr Psychiatry Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11920-020-01164-1","article-title":"Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies","volume":"22","author":"Stoffers-Winterling","year":"2020","journal-title":"Curr Psychiatry Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"Cd007667","DOI":"10.1002\/14651858.CD007667.pub3","article-title":"Pharmacological interventions for antisocial personality disorder","volume":"9","author":"Khalifa","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"12956","DOI":"10.1002\/14651858.CD012956","article-title":"Pharmacological interventions for people with borderline personality disorder","volume":"2022","author":"Stoffers-Winterling","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamapsychiatry.2016.4287","article-title":"Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis","volume":"74","author":"Cristea","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1192\/bjo.2021.34","article-title":"Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study","volume":"7","author":"Kadra-Scalzo","year":"2021","journal-title":"BJPsych Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/YIC.0000000000000021","article-title":"Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices","volume":"29","author":"Knappich","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/acps.12767","article-title":"Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder","volume":"136","author":"Mart\u00edn-Blanco","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40263-021-00852-7","article-title":"Twenty-year trends in the psychopharmacological treatment of outpatients with borderline personality disorder: a cross-sectional naturalistic study in Spain","volume":"35","author":"Pascual","year":"2021","journal-title":"CNS Drugs"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1521\/pedi_2016_30_269","article-title":"Long-term course of borderline personality disorder: a prospective 10-year follow-up study","volume":"31","author":"Alvarez-Tomas","year":"2017","journal-title":"J Disord"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/JCP.0000000000000132","article-title":"Pro re nata (as needed) psychotropic medication use in patients with borderline personality disorder and subjects with other personality disorders over 14 years of prospective follow-up","volume":"34","author":"Martinho","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13651501.2019.1576904","article-title":"Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines","volume":"23","author":"Riffer","year":"2019","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/YIC.0000000000000357","article-title":"Off-label use of second-generation antipsychotics in borderline personality disorder: a comparative real-world study among oral and long-acting injectables in Spain","volume":"36","author":"Garc\u00eda-Carmona","year":"2021","journal-title":"Int Clin Psychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","article-title":"Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders","volume":"25","author":"Bridler","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1600-0447.2011.01728.x","article-title":"Medication prescribed to people with personality disorder: the influence of patient factors and treatment setting","volume":"124","author":"Crawford","year":"2011","journal-title":"Acta Psychiatr Scand"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.4088\/JCP.14m09228","article-title":"The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services","volume":"76","author":"Paton","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/13651501.2016.1235202","article-title":"Pharmacological treatment of borderline personality disorder: a retrospective observational study at inpatient unit in Italy","volume":"21","author":"Paolini","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref32","unstructured":""},{"key":"ref33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.24095\/hpcdp.34.4.06","article-title":"Quebec integrated chronic disease surveillance system (QICDSS), an innovative approach","volume":"34","author":"Blais","year":"2014","journal-title":"Chronic Inj Can"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/ajhp\/20.3.119","article-title":"Uses of AHFS classification system","volume":"20","author":"Francke","year":"1963","journal-title":"Am J Hosp Pharm"},{"key":"ref35","unstructured":"A comparison of individual and area-based socio-economic data for monitoring social inequalities in health8594\n            PampalonR\n            HamelD\n            GamacheP\n          20108609Component of Statistics Canada Catalogue no. 82-003-XHealth Rep202009"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e053943","DOI":"10.1136\/bmjopen-2021-053943","article-title":"Prescribing of antipsychotics among people with recorded personality disorder in primary care: a retrospective nationwide cohort study using the health improvement network primary care database","volume":"12","author":"Hardoon","year":"2022","journal-title":"BMJ Open"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2146\/ajhp130221","article-title":"Quetiapine for insomnia: a review of the literature","volume":"71","author":"Anderson","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/pds.5383","article-title":"Trends in benzodiazepine and alternative hypnotic use in relation with multimorbidity among older adults in Quebec, Canada","volume":"31","author":"Gosselin","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1001\/jama.2016.3445","article-title":"Treatment indications for antidepressants prescribed in primary Care in Quebec, Canada, 2006-2015","volume":"315","author":"Wong","year":"2016","journal-title":"JAMA"},{"key":"ref40","first-page":"1","article-title":"Practice guideline for the treatment of patients with borderline personality disorder","volume":"158","year":"2001","journal-title":"Am Psychiatry Assoc Am J Psychiatry"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.7202\/1098898ar","article-title":"Services et traitements offerts aux personnes ayant un trouble de personnalit\u00e9 limite: \u00e9tat de situation au Qu\u00e9bec et perspectives d\u2019avenir","volume":"47","author":"Le Corff","year":"2022","journal-title":"Sant\u00e9 Ment Au Qu\u00e9"},{"key":"ref42","unstructured":"2003"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1037\/a0036317","article-title":"Access to psychotherapy for primary care patients with anxiety disorders","volume":"55","author":"Roberge","year":"2014","journal-title":"Can Psychol Psychol Can"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1037\/a0036296","article-title":"Gender differences in professional consultation for a mental health concern: a Canadian population study","volume":"55","author":"Cox","year":"2014","journal-title":"Can Psychol Psychol Can"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1517\/14740338.3.5.485","article-title":"Safety of benzodiazepines in the geriatric population","volume":"3","author":"Madhusoodanan","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"ref46","first-page":"e11042","article-title":"Benzodiazepine overuse in elders: defining the problem and potential solutions","volume":"12","author":"Gress","year":"","journal-title":"Cureus"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/add.15384","article-title":"Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125\u2009556 patients","volume":"116","author":"Heikkinen","year":"2021","journal-title":"Addict Abingdon Engl"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamapsychiatry.2022.3788","article-title":"Association of Pharmacological Treatments and Hospitalization and death in individuals with amphetamine use disorders in a Swedish Nationwide cohort of 13 965 patients","volume":"80","author":"Heikkinen","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/acps.13564","article-title":"Association of pharmacological treatments and real-world outcomes in borderline personality disorder","volume":"147","author":"Lieslehto","year":"2023","journal-title":"Acta Psychiatr Scand"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study","volume":"173","author":"Tiihonen","year":"2016","journal-title":"Am J Psychiatry"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1080073","DOI":"10.3389\/fphar.2023.1080073","article-title":"Psychiatric and non-psychiatric polypharmacy among older adults with schizophrenia: trends from a population-based study between 2000 and 2016","volume":"14","author":"Lunghi","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e1903","DOI":"10.1002\/mpr.1903","article-title":"Morbidities and mortality of diagnosed attention deficit hyperactivity disorder (ADHD) over the youth lifespan: a population-based retrospective cohort study","volume":"31","author":"Diallo","year":"2022","journal-title":"Int J Methods Psychiatr Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1177\/0706743717714468","article-title":"Temporal trends in the prevalence and incidence of diagnosed ADHD in children and Young adults between 1999 and 2012 in Canada: a data linkage study","volume":"62","author":"Vasiliadis","year":"2017","journal-title":"Can J Psychiatr"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neubiorev.2017.11.007","article-title":"Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: a systematic review and meta-analysis","volume":"84","author":"Ruiz-Goikoetxea","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"ref56","first-page":"1277","article-title":"ADHD medication use and psychiatric comorbidity, trauma and mortality in children and Young adults: a cohort study from Quebec, Canada","volume-title":"21st ISoP Annual Meeting \u201cA New Era of Pharmacovigilance: Challenges and Opportunities\u201d 20\u201323 September 2022 Verona, Italy. Drug Saf","author":"Lunghi","year":"2022"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jamda.2019.10.022","article-title":"Adverse outcomes of polypharmacy in older people: systematic review of reviews","volume":"21","author":"Davies","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/jech-2020-214238","article-title":"Medication adherence in community-dwelling older people exposed to chronic polypharmacy","volume":"75","author":"Franchi","year":"2021","journal-title":"J Epidemiol Community Health"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/ggi.14065","article-title":"Geriatric management of older patients with multimorbidity","volume":"20","author":"Kojima","year":"2020","journal-title":"Geriatr Gerontol Int"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"104630","DOI":"10.1016\/j.archger.2022.104630","article-title":"Association between polypharmacy and mortality in the older adults: a systematic review and meta-analysis","volume":"100","author":"Li","year":"2022","journal-title":"Arch Gerontol Geriatr"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet","volume":"5","author":"Raman","year":"2018","journal-title":"Psychiatry"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5837","article-title":"The epidemiology and clinical features of personality disorders in later life; a study of secondary care data","volume":"37","author":"Treagust","year":"2022","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0895-4356(03)00246-4","article-title":"Validation of diagnostic codes within medical services claims","volume":"57","author":"Wilchesky","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(19)32316-5","article-title":"A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study","volume":"394","author":"Plana-Ripoll","year":"2019","journal-title":"Lancet"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.3390\/jcm10122572","article-title":"Impact of cluster B personality disorders in drugs therapeutic community treatment outcomes: a study based on real world data","volume":"10","author":"Dacosta-S\u00e1nchez","year":"2021","journal-title":"J Clin Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/ADM.0000000000000992","article-title":"Pharmacotherapies for adults with alcohol use disorders: a systematic review and network meta-analysis","volume":"16","author":"Bahji","year":"2022","journal-title":"J Addict Med"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"107595","DOI":"10.1016\/j.ypmed.2023.107595","article-title":"The 3-year effects of a personality-targeted prevention program on general and specific dimensions of psychopathology","volume":"173","author":"Lynch","year":"2023","journal-title":"Prev Med"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1243511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T12:03:18Z","timestamp":1700740998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1243511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":67,"alternative-id":["10.3389\/fpsyt.2023.1243511"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1243511","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"article-number":"1243511"}}